title: [Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)].
abstract: This report summarizes results of controlled clinical studies designed to evaluate the effectiveness and safety of roflumilast, a phosphodiesterase-4 (PDE-4) inhibitor in patients with COPD and to identify the main groups of patients to whom prescription of this medication is indicated and results in reduction of repeated exacerbations. Generally speaking, roflumilast therapy appears justified for patients with symptoms of chronic bronchitis, severe or very severe bronchial obstruction (forced expiratory volume below 50%) and/or frequent exacerbations of the disease (= > 2/12 mo). Manifestations of symptomatic COPD (dyspnea, cough, expectoration, tolerance of physical exercises, etc.) are immaterial for taking decision to introduce roflumilast in combined therapy of COPD.
authors.forename: A I
authors.initials: AI
authors.lastname: Sinopal'nikov
mesh_terms: D000631:Aminopyridines / Q000494:pharmacology* / Q000627:therapeutic use; D001549:Benzamides / Q000494:pharmacology* / Q000627:therapeutic use; D029481:Bronchitis, Chronic / Q000188:drug therapy*; D018849:Controlled Clinical Trials as Topic / Q000639:trends; D003521:Cyclopropanes / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D058988:Phosphodiesterase 4 Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000517:prevention & control*
chemical_list: D000631:Aminopyridines; D001549:Benzamides; D003521:Cyclopropanes; D058988:Phosphodiesterase 4 Inhibitors; C424423:Roflumilast